✦ LIBER ✦

Crossroads in GDNF therapy for Parkinson's disease

✍ Scribed by Todd B. Sherer; Brian K. Fiske; Clive N. Svendsen; Anthony E. Lang; J. William Langston

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 68 KB
Volume: 21
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.20861

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society

📜 SIMILAR VOLUMES

Neuroprotective Therapy for Parkinson's

Neuroprotective Therapy for Parkinson's disease

✍ I.Shoulson and the Parkinson Study Group 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

In the context of degenerative disorders of the basal ganglia, neuroprotective therapy refers to interventions that preserve the integrity and function of vulnerable neurons and thereby slow or halt clinical decline. Decoppering therapy for Wilson's disease is the only established neuroprotective th

Milacemide therapy for Parkinson's disea

Milacemide therapy for Parkinson's disease

✍ M. E. Giuffra; V. H. Sethy; T. L. Davis; M. M. Mouradian; Dr. T. N. Chase 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

## Abstract The clinical effects of central glutamatergic stimulation by the glycine prodrug milacemide were studied in six patients with Parkinson's disease under double‐blind, placebo‐controlled conditions. When administered as monotherapy at a single oral dose of 1,200 mg, the drug increased ove

Gene therapy for Parkinson's disease

✍ Tomas Bjorklund; Jeffrey H. Kordower 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB

## Abstract The once fantastic theoretical concept that patients with Parkinson's disease (PD) would receive gene therapy in an attempt to alleviate their symptoms and potentially modify the course of their disease has become a reality. On the basis of positive preclinical data, four different gene

Mitochondrial therapies for Parkinson's

Mitochondrial therapies for Parkinson's disease

✍ Bobby Thomas; M. Flint Beal 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 1 views

## Abstract Parkinson's disease (PD) is marked by widespread neurodegeneration in the brain in addition to a selective yet prominent and progressive loss of nigrostriatal dopaminergic neurons. Of the multiple theories suggested in the pathogenesis of PD, mitochondrial dysfunction takes a center sta

Initiating therapy in Parkinson's diseas

Initiating therapy in Parkinson's disease

✍ William Weiner; Eric Ahlskog; Stewart Factor; Oksana Suchowersky; Stephen Reich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 51 KB 👁 2 views

Speech therapy in Parkinson's disease

📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB